Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%

Follow VTRS

Alert me

Market cap: $20.9B
P/E: 0.0×
Fwd P/E: 61.1×
Dividend yield: 2.57%
F-score: 4/9
Altman Z: 0.61
Beneish M: −3.29
Dividend safety: 37/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	—	1	—	—	—	—

Insider Ownership 3.72%

Capital & Financial Ratios $m

Market Cap 20,930.00

Revenue 14,737.30

Net Income (410.70)

Free Cash Flow 1,890.60

Net Debt 12,464.80

Current Ratio 1.58

Debt/Equity 0.94

P/E ratio 0.00

Fwd P/E 61.10

P/S ratio 1.47

P/B ratio 1.52

Past 5Y EPS Growth —

This Y EPS Growth 7.21%

Next Y EPS Growth 6.69%

Next Y revenue growth 3.43%

Next 5Y EPS Growth 6.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.01%

10-year low 10-year high

P/B against its own 10 years 77.96%

10-year low 10-year high

EV/Sales against its own 10 years 59.90%

10-year low 10-year high

EV/FCF against its own 10 years 52.75%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.48

Annual Dividend Yield 2.57%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.51	0.12 0.12 0.12
2025	0.48	0.12 0.12 0.12 0.12
2024	0.48	0.12 0.12 0.12 0.12
2023	0.48	0.12 0.12 0.12 0.12
2022	0.48	0.12 0.12 0.12 0.12
2021	0.33	0.11 0.11 0.11
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	992	735	1,322	887
Receivables	3,700	3,221	3,031	3,126
Inventory	3,470	3,854	3,999	3,933
Other	2,786	—	—	—
	12,976	9,521	9,789	10,056

	2023	2024	2025	Q'26
Payables	1,938	1,854	1,754	1,727
ST’ Debt	1,943	8	1,933	1,739
Other	3,669	3,725	3,283	2,880
	7,777	5,779	7,094	6,346

Compound Annual Growth %

	10y	5y	3y
Sales	4.25%	3.66%	(4.20%)
Cash Flow	1.43%	13.46%	(8.26%)
Earnings	0.00%	0.00%	0.00%
Book Value	4.18%	(8.51%)	(11.29%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3,517	3,757	—	—	—
’25	3,254	3,582	3,760	3,704	14,300
’24	3,663	3,797	3,751	3,528	14,739
’23	3,729	3,919	3,942	3,837	15,427
’22	4,192	4,117	4,078	3,876	16,263
’21	4,430	4,578	4,537	4,342	17,886
’20	2,619	2,731	2,972	3,624	11,946

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	388	382	—	—	—
’25	536	220	745	816	2,316
’24	615	379	827	483	2,303
’23	971	525	835	569	2,900
’22	1,139	803	869	189	2,999
’21	849	559	1,086	523	3,017
’20	291	380	525	36	1,232

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	268	336	—	—	—
’25	485	167	646	640	1,939
’24	805	747	2,574	339	4,466
’23	889	449	781	684	2,804
’22	1,072	721	754	24	2,570
’21	808	543	967	207	2,526
’20	181	327	467	(422)	553

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.15	(0.10)	—	—	—
’25	(2.55)	0.00	(0.11)	(0.30)	(3.00)
’24	0.09	(0.27)	0.08	(0.43)	(0.53)
’23	0.19	0.22	0.27	(0.64)	0.05
’22	0.33	0.26	0.29	0.83	1.71
’21	(0.86)	(0.23)	0.26	(0.22)	(1.05)
’20	0.04	0.08	0.36	(1.59)	(1.11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	33.60	29.39	26.03	16.63	12.75	11.96	8.42	8.74	9.93	6.85	Analyst estimates 2026–2028 Powerpack
	High	54.44	45.87	47.82	32.23	23.11	18.77	15.60	12.40	13.62	12.62
People
People	Employees	35,000	35,000	35,000	35,000	45,000	37,000	37,000	38,000	32,000	30,000
	Revenue/emp, $m	0.32	0.34	0.33	0.33	0.27	0.48	0.44	0.41	0.46	0.48
Income, $m
Income, $m	Revenue	11,077	11,908	11,434	11,501	11,946	17,886	16,263	15,427	14,739	14,300
	Gross margin, %	42.40	40.17	35.00	33.89	31.78	31.17	39.95	41.74	38.15	35.06
	EBT	122	903	298	154	(721)	(664)	2,813	203	(623)	(3,665)
	EBT margin, %	1.10	7.58	2.61	1.34	(6.04)	(3.71)	17.30	1.32	(4.23)	(25.63)
	Net income	480	696	353	17	(670)	(1,269)	2,079	55	(634)	(3,515)
	Depreciation	1,523	1,806	2,110	2,019	2,216	4,507	3,028	3,321	3,214	5,735
Per share, $
Per share, $	Revenue	21.59	22.28	22.22	22.30	19.87	14.80	13.42	12.85	12.35	12.21
	Earnings	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)	(3.00)
	Cash flow	3.99	3.86	4.55	3.50	2.05	2.50	2.47	2.42	1.93	1.98
	Capex	(1.46)	(1.51)	(2.27)	(0.73)	(1.13)	(0.41)	(0.35)	(0.08)	1.81	(0.32)
	Free cash flow	2.53	2.35	2.28	2.76	0.92	2.09	2.12	2.34	3.74	1.66
	Book value	21.67	24.90	23.65	23.04	38.18	16.95	17.39	17.05	15.62	12.57
	Shares, m	513	535	515	516	601	1,209	1,212	1,200	1,193	1,171
Valuation, ×
Valuation, ×	P/E	42.98	32.91	40.29	670.00	0.00	0.00	6.66	227.80	0.00	0.00
	P/S	1.81	1.94	1.23	0.90	0.94	0.91	0.85	0.89	1.01	1.02
	P/B	1.80	1.73	1.16	0.87	0.49	0.80	0.65	0.67	0.80	0.99
	EV/Sales	3.25	3.25	2.41	2.05	3.24	2.17	1.96	2.00	2.04	1.93
	EV/FCF	27.74	30.83	23.46	16.53	70.10	15.34	12.38	10.99	6.74	14.27
Cash, $m
Cash, $m	Operating cash flow	2,047	2,065	2,342	1,804	1,232	3,017	2,999	2,900	2,303	2,316
	Capex	(751)	(809)	(1,166)	(378)	(679)	(491)	(429)	(96)	2,163	(377)
	Free cash flow	1,297	1,255	1,175	1,426	553	2,526	2,570	2,804	4,466	1,939
Balance, $m
Balance, $m	Working capital	2,482	828	1,780	1,188	2,305	1,019	3,889	5,199	3,741	2,695
	Total debt	16,898	15,956	13,863	13,683	28,322	23,088	19,274	18,132	15,986	16,429
	Net debt	15,899	15,664	13,475	13,208	27,477	22,386	18,014	17,140	15,252	15,106
	Shareholders’ equity	11,118	13,308	12,167	11,884	22,954	20,493	21,072	20,467	18,636	14,711
Returns, %
Returns, %	ROA	1.68	1.97	1.03	0.05	(1.44)	(2.18)	3.96	0.11	(1.42)	(8.93)
	ROIC	1.62	3.10	2.21	1.78	(0.26)	(0.05)	2.58	1.27	0.02	(5.58)
	ROE	4.60	5.70	2.77	0.14	(3.85)	(5.84)	10.00	0.26	(3.24)	(21.08)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TAK Takeda Pharmaceutical Co.	$61.9B	29.6×	—	+1.71% (above 0%: growing)	−4.35% (below 0%: shrinking)	−95.56% (below 0%: shrinking)	66.66%	16.51%	Compare
TEVA Teva Pharmaceutical Industries Ltd.	$47.9B	65.9×	30.7×	−0.81% (below 0%: shrinking)	n/m	+121.43% (above 0%: growing)	51.98%	(2.03%)	Compare
HLN Haleon PLC Sponsored ADR	$43.7B	22.6×	17.6×	−0.32% (below 0%: shrinking)	+40.00% (above 0%: growing)	−42.94% (below 0%: shrinking)	62.88%	25.36%	Compare
ZTS Zoetis Inc.	$32.4B	13.0×	12.3×	−0.24% (below 0%: shrinking)	+2.48% (above 0%: growing)	+17.43% (above 0%: growing)	72.73%	37.56%	Compare
UTHR United Therapeutics Corporation	$23.2B	17.6×	20.1×	−1.92% (below 0%: shrinking)	+13.99% (above 0%: growing)	+58.76% (above 0%: growing)	87.30%	42.23%	Compare
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
Median of peers	$27.8B	22.6×	24.3×	−0.28%	+13.99%	+26.50%	64.77%	16.16%

All 86 Drug Manufacturers Specialty & Generic stocks →

Viatris Inc. (VTRS) key facts

Concern: Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
Viatris Inc. (VTRS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VTRS traded at $18.66, a market capitalization of $20.9 billion.
Viatris Inc. pays an annual dividend of $0.48 per share, a yield of 2.57%.
Return on equity was −21.1% and debt-to-equity 0.94.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.61 (distress zone) for fiscal 2025.